Drugs / RGLS4326
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04536688 | Oct 2020 → Nov 2021 | autosomal dominant polycystic kidney disease | Regulus Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGLS4326 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04536688 ↗ |
| Route | Subcutaneous | “RGLS4326 administered via SC injection” NCT04536688 ↗ |